DISCUSSION
tumor, myalgia, cancers, neutropenia, fatigue, fever, cancer, bone pain, pain, high‐intensity, sarcomaBone marrow suppression, tumors
ADVERSE REACTIONS, TUMOR, CANCERS, NEUTROPENIA, CANCER, COMPLICATION, TUMORS, PEDIATRIC CANCER
Pegfilgrastim is a PEG‐rhG‐CSF approved in the United States, but the documented evidence was based on very small sample size.In previous studies, the main adverse reactions after PEG‐rhG‐CSF administration in adult and pediatric patients included bone pain, myalgia, fever, and fatigue.The incidence and duration of severe neutropenia with PEG‐rhG‐CSF (Jinyouli) were comparable to pegfilgrastim in pediatric patients with sarcomaBone marrow suppression after high‐intensity chemotherapy for childhood tumors is the most common complication. PEG‐rhG‐CSF has the following advantages over rhG‐CSF. First of all, it reduces the number of injections, thereby reducing pain in pediatric patients and improving compliance. Secondly, compared with rhG‐CSF, PEG‐rhG‐CSF has a lower neutropenia rate in the subsequent chemotherapy cycle.This study has limitations. This study included patients with different tumor types and high‐intensity chemotherapy regimens. The sample size is too small, and the variability in cancers and chemotherapy regimens is too wide to allow any meaningful subgroup analysis.In conclusion, prophylactic PEG‐rhG‐CSF can be used in pediatric cancer patients. The present study suggests that PEG‐rhG‐CSF injection is convenient, safe, and effective in pediatric patients with cancer receiving high‐intensity chemotherapies. Future studies are warranted to explore the efficacy differences among various tumor types.